**Summary**
Venture Life Group PLC (AIMVLG) released a trading update for the twelve-month period ended December 31, 2025, highlighting significant growth and strategic developments. The company reported revenues of £35.1 million, a 32.0% increase from the previous year, driven primarily by its Power Brands (Balance Activ, Lift/Glucogel, Earol, Health & Her/Him), which grew by 14.9% to £33.1 million. UK revenues surged by 20.7% to £25.7 million, supported by increased advertising and promotion (A&P) spend, while international revenues declined by 8.7% to £9.4 million due to order timing and temporary disruptions.
Key brand performances included
**Balance Activ**+37.0% to £4.3 million
**Earol**+11.5% to £3.2 million
**Lift**+4.9% to £7.3 million
**Health & Her/Him**+44% proforma to £8.5 million
The company has shifted focus to becoming a pure branded consumer healthcare business, divesting its CDMO operations and restructuring its international business to prioritize strategic partnerships for stable growth. Investments in new product development (NPD) and digital technologies, including the Microsoft Dynamics 365 ERP system, are expected to drive future revenue growth.
As of December 31, 2025, Venture Life held a net cash position of £34.4 million and continued its share buyback program, returning £1.1 million to shareholders. The company remains confident in achieving its revenue and Adjusted EBITDA targets for the seventeen-month accounting period ending May 31, 2026, and is actively pursuing M&A opportunities in complementary sectors.
CEO Jerry Randall emphasized the success of increased A&P spend, the strong performance of womens health brands, and the companys strategic pivot toward supporting proactive healthy longevity. Venture Life enters 2026 with momentum, a reshaped business model, and a focus on leveraging its enhanced capabilities for future growth.